George D. Demetri - Concepedia

Author

George D. Demetri

Also Known As

Demetri, George D., G D Demetri, G Demetri, G. D. Demetri, G. Demetri, G.D. Demetri, G.D.D. Demetri, George D Demetri, George D. Demetri, George Demetri

199

Publications

17K

Citations

H-Index

135

Concepts

All Affiliations

Dana-Farber Cancer Institute Harvard University Brigham and Women's Hospital Memorial Sloan Kettering Cancer Center Massachusetts General Hospital

About

George D. Demetri is an author at Dana-Farber Cancer Institute specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	48	7.8K
2	Health Sciences	14	15	1.8K
3	Public Health	5	5	2.2K
4	Natural Sciences	1	1	283
5	Allergy	1	1	271

George D. Demetri

Publications

15.4K

Citations

H-Index

Page 1

	Year	Citations
Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children Alexander Drilon, Theodore W. Laetsch, Shivaani Kummar, New England Journal of Medicine	2018	2.6K
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah, The Lancet EpidemiologyCancer EpidemiologyMedicineGlobal HealthEpidemiology Of Cancer	2020	1.8K
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials Robert C. Doebele, Alexander Drilon, Luis Paz‐Ares, The Lancet Oncology	2019	1.7K
2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline Thomas J. Smith, James Khatcheressian, Gary H. Lyman, Journal of Clinical Oncology	2006	1.6K
2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines Howard Ozer, Jamés O. Armitage, Charles L. Bennett, Journal of Clinical Oncology ImmunohematologyPreclinical TherapeuticsPopulation Health SciencesPathologyAmerican Society	2000	1K
Crizotinib in<i>ALK</i>-Rearranged Inflammatory Myofibroblastic Tumor James E. Butrynski, David R. D’Adamo, Jason L. Hornick, New England Journal of Medicine Lymphoid NeoplasiaTumoral PathologyMalignant DiseaseAlk-translocated ImtPathology	2010	851
Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking <i>KIT</i> and <i>PDGFRA</i> mutations Katherine A. Janeway, Su Young Kim, Maya Lodish, Proceedings of the National Academy of Sciences Complex Ii ActivitySuccinate DehydrogenaseSomatic VariantAlcohol DehydrogenasesBiochemistry	2010	603
Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy Jeffrey Crawford, David Cella, Charles S. Cleeland, Cancer	2002	431
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study Mrinal M. Gounder, Patrick Schöffski, Robin L. Jones, The Lancet Oncology Tumor BiologyMedicineBasket StudyPathologyImmune Checkpoint Inhibitor	2020	383
Clinical Cancer Advances 2008: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology Eric P. Winer, Julie R. Gralow, Lisa Diller, Journal of Clinical Oncology Cancer ManagementEpidemiology Of CancerPathologyAmerican SocietyUnited States	2008	286

Page 1